Search All News
Source:Department of Pediatrics
A team of Columbia physician-scientists have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier to better treat pediatric brain tumors.
Dr. Gill is focused on improving therapies for patients with brain cancer and shares why building thoughtful mentor-mentee relationships are critical in science and medicine.
Translational scientist Robert Wechsler-Reya, PhD, an expert in pediatric brain cancer, has joined the Herbert Irving Comprehensive Cancer Center as scientific director of Brain Tumor Research.
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
Source:CUIMC NewsroomJuly 18, 2022
Dr. Ben Izar and collaborators have completed one of the most comprehensive studies of the cells inside melanoma brain metastases, uncovering details that could spur development of novel therapies.
- June 30, 2022
Three multi-disciplinary research teams have been awarded the 2022 Irving Multi-PI Planning Grant to fuel innovative research and treatment.
Source:NRG OncologyJune 28, 2022
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
- March 28, 2022
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.
- February 4, 2022
A clinical trial led by Columbia neuro-oncology team suggests that a new type of anti-cancer drug has promise for patients with glioblastoma.
- July 8, 2021
New clinical trial studies the application of focused ultrasound technique to deliver chemotherapy in patients with DIPG, an aggressive type of brain cancer.
Source:CUIMC NewsroomJanuary 11, 2021
A study, led by HICCC members, has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.